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The number of solid organ transplants performed in the United States continues to increase annually as
does survival after transplant. These unique patients are increasingly likely to present to arthroplasty
surgeons for elective hip or knee replacement secondary to a vascular necrosis from chronic immuno-
suppression, or even age-related development of osteoarthritis. Transplant recipients have a well-
documented increased risk of complications but also excellent pain relief and dramatic improvement in
quality of life. A multidisciplinary approach with the assistance of the medical transplant services for risk
stratiﬁcation and perioperative medical optimization is necessary. Prior solid organ transplant is not a
contraindication to surgery; however, it is the responsibility of the surgeon to educate patients about the
relative risks and beneﬁts of prior to surgery.
Copyright © 2015 Published by Elsevier Inc. on behalf of American Association of Hip and Knee Surgeons.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Introduction
The Annual Report of the U.S. Organ Procurement and Trans-
plantation Network demonstrated the increased incidence of all
solid organ transplantations (kidney, liver, lung, heart) in recent
years [1]. Kidney transplants encompassed the vast majority of
solid organ transplants in 2013 with 17,654 procedures performed,
a 2.1% increase from the previous year. Additionally, the number of
liver transplants increased 3.2% to 6455 and heart transplants
increased 6.1% to 2554 procedures. Lastly, the number of lung
transplants performed in the United States increased by 9.1%
to 1946 procedures in 2013. Aside from the increasing prevalence of
transplant procedures performed annually, improved surgical
technique, patient selection, perioperative care, and post-
transplant immunosuppression regimens has led to improved
graft survival and life expectancies for transplant recipients [1].losed potential or pertinent
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d/4.0/).Table 1 summarizes the most recently reported ﬁve year survi-
vorship, as well as the volume of the four major organ transplants
in the United States.
Postoperative medical regimens for transplant recipients inﬂu-
ence consideration for elective hip or knee arthroplasty. Newer
immunosuppressive regimens including tacrolimus and myco-
phenalate have decreased the need for corticosteroids, but chronic
immunosuppression has lasting consequences beyond infection
risk. While immunosuppression is associated with osteonecrosis of
the hip and knee, and represents the more traditional indication for
consideration of joint replacement surgery, these agents in com-
bination with chronic steroid use may result in poor bone quality
and potential for periprosthetic fracture or prosthesis failure.
Clearly, improved graft and patient survivorship with modern
transplant surgery means that patients are living longer, more
active lives. As such, degenerative disease secondary to osteoar-
thritis is becoming a common indication for joint replacement in
this rare population.
Recipients of successful organ transplantation experience sub-
stantial gains in functional status and relish the opportunity to
regain independence. Degenerative joint disease, as result of
avascular necrosis or osteoarthritis, may signiﬁcantly hinder func-
tional independence and even limit cardiopulmonary rehabilita-
tion. As this unique patient population continues to expand,
arthroplasty surgeons will inevitably be facedwith patients seeking
elective joint replacement. The purpose of this report is to combinen of Hip and Knee Surgeons. This is an open access article under the CC BY-NC-ND
Table 1
Case volume and ﬁve year survivorship by organ transplanted in the United States





Data from 2012/2013 OPTN/SRTR Annual Data Report and United States Renal Data
System 2011 Annual Report.
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mendations regarding perioperative optimization to improve
patient outcomes.Case history
Formal informed consent was obtained from patient (RC) for
inclusion in this article as a case example of a typical transplant
recipient treated with elective joint replacement at our institu-
tion. RC was a 66 year old male that presented to the orthopaedic
clinic with end-stage hip osteoarthritis nearly 14 years status-
post cardiac transplantation for heart failure (Fig. 1). His hip
disease resulted in severe pain aggravated by everyday activity
and signiﬁcantly diminished his quality of life and ability to
perform cardiopulmonary exercise. RC was diagnosed with
advanced osteoarthritis of the right hip. He was deemed a
candidate for arthroplasty with the caveat that he would require
a formal consultation with his medical transplant team for risk
stratiﬁcation; if the medical team agreed elective arthroplasty
was appropriate, he would then return to orthopaedic clinic for a
preoperative appointment. RC wished to proceed with arthro-
plasty and, as such, he was referred back to his heart transplant
medical doctor for preoperative evaluation. Serum levels of his
immunosuppression drugs (cyclosporine and mycophenolate)
were stable, he had no evidence of graft rejection, and a recent
cardiac catheterization was normal. His transplant cardiology
team obtained a preoperative echocardiogram, which was also
normal, and RC was deemed low risk for cardiovascular compli-
cation and cleared for surgery. Recommendations were made toFigure 1. Low AP x-ray of the pelvis demonstrating signiﬁcant end-stage osteoarthritis
of the right hip.continue immunosuppression and antihypertensive (amlodipine,
labetalol) regimens perioperatively. RC then returned to the or-
thopaedic clinic for his preoperative visit. After a thorough dis-
cussion of the risks, beneﬁts, and appropriate expectations
related to elective joint replacement in the setting of chronic
immunosuppression and history of solid organ transplantation,
RC chose to proceed with total hip arthroplasty (THA), formal
operative consent was obtained, and he was given a surgical date.
Right total hip arthroplasty was performed via posterior
approach uneventfully. He received three doses of perioperative
cefazolin (the standard antibiotic prophylaxis at our institution),
and low-molecular-weight heparin was used for deep venous
thrombosis (DVT) prophylaxis. RC was discharged home on post-
operative day 2 with no complications and did not require peri-
operative in-hospital consultation with the respective medical
transplant service. His recovery was uneventful and without any
wound complications. At one year follow up, radiographs were
stable (Fig. 2), RC reported zero hip pain and a recent return to
recreational golf.
Eighteen months postoperatively, RC was interviewed
regarding his THA. When asked his overall impression of hip
replacement surgery now that he was 18 months out from surgery
he answered, “It was wonderful. I now have a high quality life.
Before my hip was replaced I couldn't do anything; I could barely
walk in my house. Now I am walking with no pain and golﬁng as
much as I can.” When what advice he would you give someone
with a transplant considering joint replacement, he responded, “If
anyone with a transplant is leery of joint replacement, I would
love to persuade them to have it done. My advice would be to have
it done as soon as possible. I put it off for a year and looking back I
was dumb.”Discussion
An increased rate of complications after hip and knee
arthroplasty in organ transplant recipients is well documented
[2e8], but with excellent patient satisfaction also described [7,8],
surgeons and patients are left to weigh risks and beneﬁts prior to
undertaking elective, primary joint replacement. However, a
recent study by Cavanaugh et al., which analyzed National
Inpatient Sample (NIS) data from 1993 to 2011, revealed thatFigure 2. Post-operative x-ray one year following successful right total hip arthroplasty.
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plant patients than primary procedures [2]. Their study
compared in-hospital complications in a total of 4493 patients
with a history of at least one organ transplant to non-transplant
patients. The study group comprised a mere 0.17% of the NIS
patient sample that had undergone hip or knee arthroplasty
during the study period. Overall, the most common in-hospital
complication in all transplant recipients was acute renal failure
(ARF). For comparative analysis, cardiac, lung and pancreas
transplant patients were grouped together and collectively found
to have a slightly higher risk of respiratory and wound compli-
cations when compared to kidney and liver recipients. As could
be expected, transplant patients undergoing revision surgery had
higher rates of complications than those undergoing primary
procedures.
Ledford et al. reviewed 76 patients undergoing primary
arthroplasty after solid organ transplantation at a single institution
and reported an overall complication rate of 29% in THA and 33% in
total knee arthroplasty (TKA), although they included minor com-
plications such as electrolyte abnormalities requiring medical
intervention in their analysis [3]. The authors also found ARF to be
one of the most common complications following surgery. The
etiology of ARF in this population is likely multifactorial depending
upon preoperative hemoglobin levels, clotting factors, cardiopul-
monary volume capacity, perioperative medication nephrotoxicity,
and baseline renal function. Interestingly, this study also found that
the rate of symptomatic anemia requiring transfusionwas higher in
cardiac and lung transplant patients, likely reﬂecting the fact that
these speciﬁc transplant populations are unable to tolerate even
minor variations in hemoglobin levels in the setting of potentially
limited cardiopulmonary reserve.
Infection is perhaps the greatest perioperative and late post-
operative concern. There are increased rates of periprosthetic
infection (PPI) in all organ recipients with ranges varying in the
literature between 3.2 and 17.3% [3e7].While pathogens aremainly
caused by gram positive bacteria, there are reports of opportunistic
pathogens such as nontuberculous mycobacteria [6] and E. coli [5].
Reoperation for any indication has been investigated by several
studies. Beyond infection, the underlying poor bone quality in
organ transplant recipients associated with periprosthetic fracture,
instability and aseptic loosening contributes to the reoperation
rate. Angermeier et al. reported a 13% overall reoperation rate (6.8%
noninfectious) in 68 solid-organ transplant patients after hip or
knee arthroplasty [3]. This was nearly identical to the 12.9% (7.7%
noninfectious) reported by Ledford et al. [3]. Klatt et al. investigated
19 organ recipients undergoing primary hip or knee arthroplasty
and reported a reoperation rate of 39.1% [5].
An unpublished study from our institution conﬁrms the
increased risk of arthroplasty in organ transplant recipients in the
Medicare population. A PearDiver analysis of a comprehensive
Medicare database of all enrollees from 2005 to 2011 was per-
formed identifying THA patients with a pre-existing solid organ
transplant. There were a total of 3180 patients who underwent THA
after one or more various solid OTs (2312 kidney transplants, 561
liver transplants, 196 lung transplants, 428 heart transplants, 149
pancreas transplants). A cohort of 771,498 patients who underwent
elective primary THAwithout prior history of solid organ transplant
served as a control. Incidence (IN), odds ratios (ORs) and their
respective 95% conﬁdence intervals (CIs) for 30-day, 90-day and
overall complications were calculated. The most notable overall
increased risks in the transplant cohort include: acute renal failure
(IN 76%, OR 13), blood transfusion (IN 48%, OR 1.6), arthrotomy/I&D
(IN 2%, OR 1.6), DVT/PE (IN 11%, OR 2.1), mortality (IN 0.6%, OR 1.9),
periprosthetic infection (IN 4.3%, OR 1.7), wound complications (IN
2.6%, OR 2.3), and wound infection (IN 16%, OR 2.0).Based on our experience and the literature, a thorough and frank
conversation should be pursued with the patient regarding ex-
pectations. Given their underlying systemic illness and chronic
immunosuppression, surgical risk is signiﬁcantly higher, as dis-
cussed previously. Anticipated total gain and pain relief after
arthroplasty should be considered during preoperative consulta-
tion. Referring back to Table 1 the ﬁve year patient survivorship
after organ transplantation warrants dialogue given the post-
operative rehabilitation period. That being said, organ recipients
tend to have high satisfaction after arthroplasty with numerous
studies reporting good pain relief and functional outcomes [3,6,8].
Ultimately, the decision to undergo an elective procedure lies with
the patient, and it is the responsibility of the surgeon to provide
realistic expectations regarding risks and potential functional gains
in the informed consent process.
Preoperative risk stratiﬁcation and optimization is of upmost
importance. For this reason, it is imperative that patients be seen by
the respective medical transplant specialist and undergo appro-
priate preoperative testing. While the transplant team should also
discuss potential complications with patients, their primary func-
tion is to risk stratify potential arthroplasty patients to facilitate
informed decision making, make necessary preoperative in-
terventions to medically optimize the patient, and provide rec-
ommendations for perioperative management. Meriting particular
discussion is the lung transplant recipient given their unadjusted
median survival rates of 53% at 5 years and only 30% after 10 years
[9]. In fact, there are several pulmonary transplant physicians at our
institution who request lung transplant patients to be admitted to
the pulmonary service postoperatively, with the arthroplasty team
to strictly manage orthopaedic issues only. Generally, all immu-
nosuppression regimens should be resumed preoperatively and
immediately postoperatively, unless they are taking sirolimus
which has been associated with increased infection risk [10].
Postoperatively, there should be a very low threshold, and some-
times automatic trigger for involving the medical specialists once
the patient is admitted to the ﬂoor. Their expertise on transplant
speciﬁc medicine reconciliation, ﬂuid management, vital sign ab-
normality, and inpatient hospital course is superior to that of the
orthopaedist and should be utilized.
Anesthesia can play an important role in the transplant
recipient's hospital course and outcome. Given their decreased
baseline cardiopulmonary and hepatorenal function, avoiding
excessive insults is of paramount importance. For that reason, we
prefer spinal or regional catheters as they will reduce the patient's
systemic load of anesthetic. Postoperatively, we prefer a multi-
modal pain regimen to limit postoperative discomfort, decrease
narcotic intake, and facilitate early ambulation with physical ther-
apy all in an effort to minimize cardiopulmonary complications.
Unfortunately, there are contraindications to amultimodal regimen
(for example NSAIDs in renal patients) and for that reason we rely
upon the coordination among anesthesia and transplant medical
specialists. Judicious ﬂuid management is necessary to prevent
acute renal failure. In some circumstances, maintenance ﬂuids are
contraindicated due to their delicate cardiopulmonary function.
Again, we directly involve the medical specialists to determine
colloid administration or blood transfusion in any complex case.
Our transfusion threshold is quite low in transplant recipients
because end organ function is inhibited during anemia, and any
small ﬂuctuation in their organ function may result in graft
dysfunction. We will typically transfuse a patient for a hematocrit
<25 or evidence of end organ hypoperfusion. Our institution has a
large lung transplant program and, for this reason, our experience
with this speciﬁc transplant population is somewhat unique. Our
experience with lung transplant recipients has taught us that with
their restricted pulmonary function and tenuous volume status,
KEY POINTS
 Surgical risk is increased in organ transplant recipients un-
dergoing total joint replacement, and patients should un-
derstand this prior to their intervention.
 Multidisciplinary cooperation is mandatory to minimize
complications and maximize outcomes in organ transplant
recipients undergoing total joint replacement.
 Perioperative protocols are very helpful for surgical man-
agement and may differ from standard total joint protocols
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ﬂuid resuscitation can result in pulmonary edema. Blood trans-
fusion thresholds tend to be the lowest with this transplant pop-
ulation for volume repletion. As a result, it is our preference to
proactively involve the pulmonary transplant service in post-
operative medical management of all lung transplant patients.
While chronically immunosuppressed patients are vulnerable to
opportunistic infections, it appears that transplant recipient PJIs are
generally the result of the same organisms that infect immuno-
competent hosts: gram positive bacteria. Particular attention to
infection should be paid to patients a known Cytomegalovirus
infection as this will increase susceptibility to bacterial infections
[6]. However, when treating PJIs in this population, cultures should
be sent for atypical infections as well including anaerobes, fungal,
and mycobacteria.(eg transfusion parameters may differ).
 Prosthetic joint infection is more common in organ transplant
recipients undergoing total joint replacement, and atypical
infections must be considered.Current controversies and future considerations
With the exception of lung transplant recipients, our standard
protocol is to admit kidney, liver, and heart transplant recipients
after hip or knee arthroplasty to the orthopaedic service and
attempt to primarily manage the patient. If an objective abnor-
mality is encountered during the admission, we have a very low
threshold for consulting the respective medical transplant team.
There have been no previous studies which randomized patients to
either automatically receive interdisciplinary inpatient care (auto-
matic medicine consult) or primarily be managed by the ortho-
paedic team with consultation after an objective abnormality.
On January 1, 2014 the new Surgical Care Improvement Project
(SCIP) measures were announced which included aspirin as
acceptable venous thromboembolus prophylaxis following hip and
knee replacement. At our institution, our standard practice for DVT
prophylaxis in organ transplant recipients has been low-molecular-
weight heparin. To our knowledge, no study has been performed
evaluating venous thromboembolus prophylaxis this patient pop-
ulation and may be worthy of investigation.
Summary
Hip and knee arthroplasty can be safety performed in solid
organ transplant recipients with excellent pain relief and functional
outcomes. Proper precautions must be taken to minimize compli-
cations including: patient education and expectation delineation,
an interdisciplinary approach to care which includes the medicaltransplant team, and standardized perioperative protocols to
minimize risk.References
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